VALN - CDC advisory panel vote Q3 earnings likely to impact Dynavax shares this week

Shares of Dynavax Technologies (NASDAQ:DVAX) are poised to move this week due to two important events. Tomorrow, the CDC's Advisory Committee on Immunization Practices is set to discuss a universal adult hepatitis B vaccine recommendation. Dynavax could benefit with a vote in the affirmative as the company markets the Heplisav-B vaccine. Heplisav-B had $136.1M in revenue in 1H 2021, and the company says the vaccine has a U.S. market opportunity of up to $600M annually. On Thursday, Dynavax reports Q3 2021 earnings. In Q2, the company beat on both EPS and revenue. Dynavax has momentum given that many companies are using its CpG 1018 adjuvant, including in COVID-19 vaccines. Most recently, Valneva (VALN -3.4%) posted positive results on its COVID vaccine candidate, boosting both stocks. Dynavax shares also surged in September after partner Clover Biopharmaceuticals reported positive data on its COVID vaccine.

For further details see:

CDC advisory panel vote, Q3 earnings likely to impact Dynavax shares this week